Sustained GLP-1 receptor agonist therapy is linked to greater improvements in A1c levels than DPP-4 inhibitor therapy in patients with type 2 diabetes, a Danish real-world analysis shows.
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Most adults with type 2 diabetes receiving an ...
Severe Hypoglycemia Ups Cardiovascular Risk in Diabetes Two studies demonstrate no difference versus placebo for saxagliptin, alogliptin. For patients with type 2 diabetes, treatment with the ...
A recent study published in the Journal of the American Medical Association revealed that the use of sodium-glucose ...
Among the emerging therapeutic strategies for type 2 diabetes (T2D), G protein-coupled receptor 119 (GPR119) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have demonstrated promise due to ...
The American College of Physicians issued new guidelines for Type 2 diabetes treatment, which for the first time recommends the use of GLP-1s and another class of diabetes drugs called SGLT-2s ...
Initiation of sodium-glucose cotransporter-2 inhibitors (SGLT2is) was associated with a 34% lower rate of recurrent gout flare compared with initiation of dipeptidyl peptidase 4 inhibitors (DPP-4is).
In September, Indian drug manufacturer Alembic received a tentative nod from the US Food and Drug Administration (FDA) to manufacture generic alogliptin as well as the alogliptin/metformin fixed-drug ...
With regards to his pioglitazone use, he had no history of heart failure, and his ALT level was acceptable at the time of discharge at 25 U/L. Signs and symptoms of heart failure were reviewed with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results